Wedbush Reaffirms "Outperform" Rating for Compass Therapeutics (NASDAQ:CMPX)

Wedbush reaffirmed their outperform rating on shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) in a research note issued to investors on Tuesday,RTT News reports. Wedbush currently has a $8.00 price target on the stock. Wedbush also issued estimates for Compass Therapeutics' Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at $0.42 EPS and FY2028 earnings at $1.17 EPS.

CMPX has been the subject of several other reports. Guggenheim assumed coverage on Compass Therapeutics in a research report on Monday, February 24th. They issued a "buy" rating and a $12.00 target price for the company. D. Boral Capital reaffirmed a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Piper Sandler began coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group increased their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, February 10th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Compass Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $13.38.

Remove Ads

Compass Therapeutics Price Performance

Shares of CMPX stock traded down $0.15 during trading hours on Tuesday, hitting $1.46. The company had a trading volume of 1,726,053 shares, compared to its average volume of 817,976. The stock has a market capitalization of $201.89 million, a PE ratio of -3.95 and a beta of 1.40. The company's fifty day moving average is $2.76 and its 200 day moving average is $2.10. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Equities analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its holdings in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after buying an additional 112,614 shares in the last quarter. SG Americas Securities LLC boosted its stake in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after acquiring an additional 356,352 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company's stock worth $4,251,000 after purchasing an additional 19,095 shares during the last quarter. Bleakley Financial Group LLC increased its position in shares of Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company's stock worth $58,000 after purchasing an additional 28,589 shares in the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Compass Therapeutics by 218.7% during the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company's stock worth $75,000 after purchasing an additional 35,632 shares in the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.